Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.

[1]  M. Cameron,et al.  Assessment and Measurement of Spasticity in MS: State of the Evidence , 2019, Current Neurology and Neuroscience Reports.

[2]  H. Fernandez,et al.  Defining the spectrum of spasticity-associated involuntary movements. , 2019, Parkinsonism & related disorders.

[3]  Ruth Ann Marrie,et al.  The prevalence of MS in the United States , 2019, Neurology.

[4]  C. Vila,et al.  Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial , 2018, The International journal of neuroscience.

[5]  J. Sánchez-Meca,et al.  Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis. , 2018, European journal of physical and rehabilitation medicine.

[6]  Anders Larsson,et al.  Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet Neurology.

[7]  P. Vermersch,et al.  Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice , 2016, European Neurology.

[8]  C. Young,et al.  Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions , 2016, Disability and rehabilitation.

[9]  A. Thompson,et al.  Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper , 2016, Multiple sclerosis.

[10]  Ruth Ann Marrie,et al.  A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis , 2016, The Patient - Patient-Centered Outcomes Research.

[11]  A. Tennant,et al.  Spasticity in multiple sclerosis: Associations with impairments and overall quality of life. , 2016, Multiple sclerosis and related disorders.

[12]  T. Mozaffar,et al.  A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. , 2013, Critical reviews in physical and rehabilitation medicine.

[13]  C. Pozzilli,et al.  A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis , 2011, European journal of neurology.

[14]  C. Collin,et al.  A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis , 2010, Neurological research.

[15]  J. Farrar,et al.  Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. , 2008, Clinical therapeutics.

[16]  C. Collin,et al.  Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis , 2007, European journal of neurology.

[17]  A. Frotzler,et al.  Relationship between self- and clinically rated spasticity in spinal cord injury. , 2006, Archives of physical medicine and rehabilitation.

[18]  AD Pandyan,et al.  Spasticity: Clinical perceptions, neurological realities and meaningful measurement , 2005, Disability and rehabilitation.

[19]  T. Vollmer,et al.  Prevalence and treatment of spasticity reported by multiple sclerosis patients , 2004, Multiple sclerosis.

[20]  J. Wight,et al.  Treatments for spasticity and pain in multiple sclerosis: a systematic review. , 2003, Health technology assessment.

[21]  James W. Lance,et al.  The control of muscle tone, reflexes, and movement , 1980, Neurology.